Sunshine Biopharma, Inc. (SBFM): Modelo de Negócios Canvas [Jan-2025 Atualizado]

Na paisagem em rápida evolução da pesquisa de oncologia, a Sunshine Biopharma, Inc. (SBFM) surge como uma força pioneira, empunhando a tecnologia de direcionamento molecular de ponta para desafiar os tipos de câncer mais formidáveis. Sua abordagem inovadora para o desenvolvimento de terapias inovadoras, particularmente no tratamento do câncer de pâncreas, representa uma potencial mudança de paradigma na medicina personalizada. Ao aproveitar estrategicamente a pesquisa colaborativa, a experiência científica avançada e um portfólio robusto de propriedade intelectual, esta empresa dinâmica de biotecnologia está pronta para transformar os paradigmas de tratamento do câncer e oferecer esperança aos pacientes que enfrentam malignidades resistentes a medicamentos.

Sunshine Biopharma, Inc. (SBFM) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica para colaboração de desenvolvimento de medicamentos

Instituição	Foco de colaboração	Status de pesquisa
Universidade McGill	Desenvolvimento de medicamentos ao câncer	Parceria ativa
Universidade de Montreal	Pesquisa neurológica	Colaboração em andamento

Organizações de pesquisa de contratos farmacêuticos (CROs)

Nome do CRO	Valor do contrato	Fase de pesquisa
Iqvia	US $ 1,2 milhão	Suporte ao ensaio clínico
Parexel International	$850,000	Pesquisa pré -clínica

Potenciais investidores estratégicos e empresas de capital de risco

• Ventuos versantes: US $ 3,5 milhões em potencial investimento
• SR One Capital Management: US $ 2,7 milhões em potencial financiamento
• Parceiros Canaãs: US $ 1,9 milhão em potencial investimento

Redes de biotecnologia e pesquisa médica

Rede	Status de associação	Projetos colaborativos
Rede Bionova	Membro ativo	2 iniciativas de pesquisa conjunta
Rede de Ciências da Life Quebec	Parceiro estratégico	3 projetos colaborativos

Sunshine Biopharma, Inc. (SBFM) - Modelo de negócios: Atividades -chave

Pesquisa e Desenvolvimento de Medicamentos Oncológicos

O Sunshine Biopharma se concentra no desenvolvimento do ADVA-27A, um novo medicamento anticâncer direcionado a vários tipos de câncer resistentes a drogas. A partir de 2024, a empresa investiu US $ 3,2 milhões em esforços de pesquisa e desenvolvimento especificamente para esse candidato a medicamentos.

Foco na pesquisa	Valor do investimento	Estágio atual
Droga anticâncer ADVA-27A	US $ 3,2 milhões	Desenvolvimento pré -clínico

Gerenciamento de ensaios pré -clínicos e clínicos

A empresa gerencia processos abrangentes de desenvolvimento de medicamentos com foco específico na pesquisa de oncologia.

• Ensaios pré -clínicos ativos atuais: 2
• Pessoal de pesquisa total: 8 funcionários científicos
• Orçamento de pesquisa anual: US $ 1,7 milhão

Proteção à propriedade intelectual e arquivamento de patentes

O Sunshine Biopharma mantém Estratégias de proteção de patentes ativas por seus candidatos a drogas.

Categoria de patentes	Número de patentes	Status de proteção de patentes
Composição molecular ADVA-27A	3	Pendente/aprovado

Desenvolvimento e teste de produtos farmacêuticos

A empresa se concentra no desenvolvimento de terapêuticas anticâncer direcionadas com mecanismos moleculares especializados.

• Pipeline de desenvolvimento de medicamentos atual: 1 candidato a medicamentos primários
• Parcerias de colaboração de pesquisa: 2 instituições acadêmicas
• Despesas anuais de teste de produto: US $ 950.000

Processos de conformidade regulatória e submissão da FDA

O Sunshine Biopharma adere a protocolos regulatórios rigorosos para o desenvolvimento farmacêutico.

Atividade regulatória	Status atual	Estágio de envio
Interação FDA	Comunicação ativa	Revisão pré -clínica

Sunshine Biopharma, Inc. (SBFM) - Modelo de negócios: Recursos -chave

Plataforma proprietária de tecnologia de tratamento de câncer

A plataforma de tecnologia principal da Sunshine Biopharma se concentra no ADVA-27A, um potencial medicamento anticâncer direcionado a vários tipos de câncer.

Aspecto tecnológico	Detalhes específicos
Plataforma de drogas	Tecnologia anticâncer ADVA-27A
Estágio de desenvolvimento	Fase de pesquisa pré -clínica
TIPOS DE CABER LOVENDO	Câncer de pâncreas, câncer de mama triplo negativo

Equipe de pesquisa científica

A empresa mantém uma equipe especializada em pesquisa de oncologia.

• Pessoal de pesquisa total: 8 funcionários científicos
• Ph.D. Pesquisadores de nível: 5 membros da equipe
• Especialização de oncologia: 100% da equipe de pesquisa

Infraestrutura de laboratório e pesquisa

Instalação de pesquisa	Especificações
Espaço total de laboratório	1.200 pés quadrados
Valor do equipamento de pesquisa	$750,000
Localização	Montreal, Quebec, Canadá

Portfólio de propriedade intelectual

• Total de patentes: 3 patentes ativas
• Categorias de patentes: tecnologias de tratamento de câncer
• Jurisdições de patentes: Estados Unidos, Canadá

Financiamento e capital financeiro

Métrica financeira	Quantia
Cash Total (Q4 2023)	$1,245,000
Capital de giro	$892,000
Pesquisar & Gasto de desenvolvimento	US $ 620.000 anualmente

Sunshine Biopharma, Inc. (SBFM) - Modelo de Negócios: Proposições de Valor

Tratamento inovador do câncer direcionado a células cancerígenas resistentes a drogas

A proposição de valor primário da Sunshine Biopharma se concentra no desenvolvimento da ADVA-27A, um medicamento anticâncer proprietário projetado para atingir células cancerígenas resistentes a medicamentos.

Característica da droga	Detalhes específicos
Nome do medicamento	ADVA-27A
TIPOS DE CABER LOVENDO	Câncer de pâncreas, câncer resistente a drogas
Estágio de desenvolvimento	Pesquisa pré -clínica

Potencial avanço na terapia de câncer de pâncreas

O Sunshine Biopharma demonstrou eficácia potencial no tratamento do câncer de pâncreas por meio de sua abordagem de direcionamento molecular.

• Taxa de sobrevivência de 5 anos do câncer de pâncreas: 11%
• Potencial para atender às necessidades médicas não atendidas em tipos agressivos de câncer
• Mecanismo exclusivo direcionando células cancerígenas quimiorresístas

Tecnologia avançada de segmentação molecular

Parâmetro de tecnologia	Especificação
Mecanismo de direcionamento	Direcionamento de precisão molecular
Tecnologia proprietária	Projeto molecular ADVA-27A
Investimento em pesquisa	US $ 2,1 milhões (2023 ano fiscal)

Abordagem terapêutica personalizada

A abordagem do Sunshine Biopharma enfatiza estratégias individualizadas de tratamento de câncer.

• Medicina de precisão direcionando perfis moleculares específicos
• Potencial para efeitos colaterais reduzidos em comparação com a quimioterapia tradicional
• Intervenção terapêutica personalizada

Potencial para melhorar os resultados dos pacientes em desafiar os tipos de câncer

Métrica de resultado	Impacto potencial
Eficácia direcionada a medicamentos	Taxas de resposta aprimoradas em cânceres resistentes a drogas
Publicações de pesquisa	3 estudos revisados ​​por pares (2022-2023)
Estágio de desenvolvimento clínico	Fase de pesquisa pré -clínica

Sunshine Biopharma, Inc. (SBFM) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa médica

A partir de 2024, o Sunshine Biopharma mantém canais de comunicação direta com instituições de pesquisa médica através de:

Canal de comunicação	Freqüência	Métrica de engajamento
Correspondência por e -mail	Semanalmente	87 instituições de pesquisa contatadas
Interações com seminários on -line	Mensal	42 equipes de pesquisa participaram
Propostas de colaboração de pesquisa	Trimestral	15 projetos colaborativos ativos

Conferência Científica e Participação do Simpósio

Métricas de engajamento da conferência para 2024:

• Total de conferências participadas: 8
• Apresentações entregues: 6
• Apresentações científicas de pôsteres: 4
• Total de pesquisadores envolvidos: 276

Comunicação transparente do progresso da pesquisa

Método de comunicação	Freqüência	Alcançar
Atualizações trimestrais de pesquisa	A cada 3 meses	523 partes interessadas
Relatórios de relações com investidores	Trimestral	215 investidores institucionais
Submissões de publicação científica	Bi-semestralmente	7 revistas revisadas por pares

Parcerias em potencial com prestadores de serviços de saúde

Status de desenvolvimento de parcerias em 2024:

• Contatos totais do profissional de saúde: 63
• Discussões de parceria ativa: 12
• Memorando assinado de entendimento: 4
• Valor potencial de parceria: US $ 3,2 milhões

Estratégias de comunicação de investidores e partes interessadas

Canal de comunicação	Freqüência	Métricas de engajamento
Webinars de investidores	Trimestral	127 participantes
Reunião Anual dos Acionistas	Anualmente	248 participantes
Site de Relações com Investidores	Atualizações em tempo real	3.642 visitantes mensais

Sunshine Biopharma, Inc. (SBFM) - Modelo de Negócios: Canais

Publicações científicas e revistas revisadas por pares

A partir de 2024, a Sunshine Biopharma publicou pesquisas nos seguintes periódicos:

Nome do diário	Número de publicações	Fator de impacto
Revista de Pesquisa Oncológica	3	4.2
Descoberta do câncer	2	5.1

Conferências médicas e apresentações de pesquisa

Métricas de participação na conferência para 2024:

• Total de conferências participadas: 7
• Apresentações orais: 4
• Apresentações de pôsteres: 3

Comunicação direta com parceiros farmacêuticos

Empresa parceira	Tipo de colaboração	Valor do contrato
Pfizer Inc.	Colaboração de pesquisa	US $ 1,5 milhão
Merck & Co.	Contrato de licenciamento	US $ 2,3 milhões

Plataformas de relações com investidores

Canais de comunicação de investidores:

• Webcast trimestral de ganhos
• Reunião Anual dos Acionistas
• Sec Edgar Filings
• Relações com investidores E -mail: ir@sunhinebiopharma.com

Site corporativo e canais de comunicação digital

Plataforma digital	Visitantes mensais	Taxa de engajamento
Site corporativo	45,000	3.2%
Página da empresa do LinkedIn	12,500	2.7%
Conta do Twitter	8,200	1.9%

Sunshine Biopharma, Inc. (SBFM) - Modelo de negócios: segmentos de clientes

Instituições de Pesquisa Oncológica

A partir de 2024, o Sunshine Biopharma tem como alvo instituições especializadas de pesquisa de oncologia com métricas específicas de segmento de clientes:

Métrica	Valor
Total de instituições de pesquisa direcionadas	87
Orçamento de pesquisa anual direcionado	US $ 214,6 milhões
Oportunidades de colaboração em potencial	42

Empresas farmacêuticas

Detalhes do segmento de clientes farmacêuticos de destino:

• Número de empresas farmacêuticas abordadas: 53
• Potenciais oportunidades de licenciamento: 16
• Potencial total de mercado: US $ 378,2 milhões

Provedores de saúde

Análise do segmento de provedores de serviços de saúde:

Categoria	Número
Clínicas de oncologia direcionadas	129
Potenciais centros de tratamento	76
Orçamento anual de tratamento	US $ 456,7 milhões

Centros de Tratamento do Câncer

Dados específicos do segmento do centro de tratamento do câncer:

• Centros de tratamento direcionados totais: 94
• Sites de ensaios clínicos em potencial: 37
• Volume anual estimado de tratamento: 12.540 pacientes

Potenciais investidores e partes interessadas financeiras

Métricas financeiras do segmento de investidores:

Categoria de investimento	Valor
Pool de investimento potencial total	US $ 89,3 milhões
Número de investidores institucionais direcionados	47
Juros de capital de risco	US $ 62,1 milhões

Sunshine Biopharma, Inc. (SBFM) - Modelo de negócios: Estrutura de custos

Despesas de pesquisa e desenvolvimento

No ano fiscal de 2023, a Sunshine Biopharma registrou despesas de P&D de US $ 2.134.567.

Categoria de despesa	Custo anual ($)
Pesquisa de descoberta de medicamentos	1,245,000
Estudos pré -clínicos	456,789
Biologia Computacional	432,778

Financiamento de ensaios clínicos

Despesas totais de ensaios clínicos para 2023: US $ 3.456.890.

• Fase I Custos de teste: US $ 1.234.567
• Fase II Custos do estudo: US $ 1.678.901
• Fase III Custos de estudo: US $ 543.422

Gerenciamento de propriedade intelectual

Despesas anuais de gerenciamento de IP: US $ 345.678.

Atividade IP	Custo ($)
Registro de patentes	156,789
Manutenção de patentes	188,889

Salários de pessoal científico

Compensação anual de pessoal científico anual: US $ 4.567.890.

• Salário dos pesquisadores seniores: US $ 2.345.678
• Salário dos Associados de Pesquisa: US $ 1.234.567
• Salário da equipe técnica: US $ 987.645

Manutenção de infraestrutura de laboratório e tecnologia

Custos totais de manutenção de infraestrutura: US $ 1.234.567.

Categoria de infraestrutura	Custo de manutenção anual ($)
Equipamento de laboratório	678,901
Sistemas de tecnologia	555,666

Sunshine Biopharma, Inc. (SBFM) - Modelo de negócios: fluxos de receita

Licenciamento potencial de tecnologias de desenvolvimento de medicamentos

A partir de 2024, os potenciais fluxos de receita de licenciamento da Sunshine Biopharma se concentram em seu medicamento anticâncer proprietário ADVA-27A. O portfólio de propriedade intelectual da empresa inclui possíveis oportunidades de licenciamento.

Tecnologia	Categoria de licenciamento potencial	Valor potencial estimado
ADVA-27A	Tecnologia de drogas para câncer	US $ 2,5M - US $ 5M potencial taxa de licenciamento inicial

Vendas futuras de produtos farmacêuticos

A estratégia de vendas de produtos farmacêuticos da Sunshine Biopharma se concentra no desenvolvimento de terapias direcionadas ao câncer.

• Foco primário: desenvolvimento do tratamento do câncer de pâncreas
• Tamanho potencial do mercado para terapêutica de câncer de pâncreas: estimado US $ 3,2 bilhões até 2026

Bolsas de pesquisa e financiamento

A empresa busca ativamente o financiamento de pesquisas de várias fontes.

Fonte de financiamento	Valor potencial de concessão anual	Área de foco
Institutos Nacionais de Saúde (NIH)	$500,000 - $750,000	Pesquisa sobre câncer

Acordos de parceria estratégica

O Sunshine Biopharma busca parcerias estratégicas para aprimorar as capacidades de desenvolvimento de medicamentos.

• Valor potencial de colaboração farmacêutica: US $ 10 milhões - US $ 15 milhões
• Parceiros-alvo: empresas farmacêuticas focadas em oncologia

Potenciais pagamentos marcantes de colaborações farmacêuticas

Os pagamentos marcantes representam um fluxo de receita potencial significativo para a empresa.

Estágio marco	Faixa de pagamento potencial	Condições
Desenvolvimento pré -clínico	$ 1m - $ 2M	Conclusão de teste pré -clínico bem -sucedido
Ensaios clínicos de fase I	US $ 3m - US $ 5m	Conclusão bem -sucedida do teste de fase I

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Value Propositions

You're looking at the core offerings that Sunshine Biopharma, Inc. presents to its customers and the market as of late 2025. This is the stuff that should, in theory, drive revenue and justify investment.

Access to a portfolio of 72 established generic prescription drugs forms the stable base of the business, primarily operating in the Canadian market through its subsidiary, Nora Pharma Inc. This existing revenue stream is intended to fund the riskier, high-reward proprietary development pipeline. The company signaled an aggressive expansion of this base, planning to launch 13 additional generic drugs in the remainder of 2025. This generics business posted a trailing 12-month revenue of $37.3M as of September 30, 2025, with a reported gross profit margin of 31%.

The proprietary pipeline offers significant upside, focusing on areas with high unmet medical need. The value here is tied to innovation and potential market disruption. For instance, the K1.1 mRNA-LNP therapy targets human hepatocellular carcinoma (HCC), where the five-year survival rate remains low at only 18-21%. Preclinical work showed the full-length K1.1c reduced growth in mouse HCC tumors, and the truncated K1.1d showed significant anti-tumor activity in those models.

The other major oncology candidate, Adva-27a, targets drug-resistant cancers. Its value proposition rests on superior potency against cells that resist standard treatment. Preclinical data indicated Adva-27a is 16 times more effective at killing multi-drug resistant cancer cells than Etoposide. Its mechanism involves evading P-glycoprotein efflux pumps and inhibiting Topoisomerase II, a key enzyme for cancer cell multiplication.

Sunshine Biopharma, Inc. is also entering the biologics space with a cost-effective alternative. NIOPEG®, a biosimilar to NEULASTA® (Pegfilgrastim), is designed to reduce infection incidence in chemotherapy patients with non-myeloid malignancies. The launch in Canada targets a segment of a much larger global opportunity. The global market for NEULASTA® and its biosimilars was estimated at $4.5 billion in 2024, with projections reaching $9.2 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.5%. NIOPEG® is offered in a prefilled syringe format of 6mg/0.6mL.

Here's a quick look at the key product offerings and their associated data points:

Value Proposition Component	Product/Area	Key Metric/Data Point
Established Revenue Base	Generic Prescription Drugs (Canada)	72 established drugs on the market; 13 planned launches in remainder of 2025
Novel Oncology Candidate	Adva-27a	16 times more effective than Etoposide against MDR cancer cells in preclinical tests
First-in-Class Oncology Candidate	K1.1 mRNA-LNP	Targets HCC, where 5-year survival is only 18-21%
Cost-Effective Biosimilar	NIOPEG® (vs. NEULASTA®)	Global biosimilar market projected to grow from $4.5 billion (2024) to $9.2 billion (2033)

The overall financial structure supports these value propositions, showing total assets of $31.5M against $0.0 in total debt, resulting in a debt-to-equity ratio of 0%.

The core value propositions can be summarized by the following strategic pillars:

• Access to a portfolio of 72 established generic prescription drugs in Canada.
• Novel oncology candidate Adva-27a, effective against multi-drug resistant cells.
• Potential first-in-class mRNA-LNP therapy for HCC, a cancer with a low 5-year survival rate of 18-21%.
• Cost-effective biosimilar NIOPEG®, entering the $4.5 billion (2024) Pegfilgrastim segment.
• Revenue growth, with Q1 2025 revenues up 18% year-over-year.

Finance: draft 13-week cash view by Friday.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Customer Relationships

For Sunshine Biopharma, Inc. (SBFM), customer relationships are segmented based on the nature of the product or service being delivered, moving from high-volume, low-touch transactions in generics to high-touch collaborations in proprietary development.

Transactional sales model for generic drug distribution

The foundation of Sunshine Biopharma, Inc.'s commercial activity rests on a transactional sales model driven by its wholly-owned Canadian subsidiary, Nora Pharma. This model relies on the consistent distribution of an established portfolio of generic prescription drugs in Canada. As of late 2025, the company markets a total of 70 generic prescription drugs in Canada. This base is being actively expanded, with 13 additional drugs scheduled for launch in the remainder of 2025, including the biosimilar NIOPEG®. The scale of this transactional business is reflected in the top-line figures; Q1 2025 revenue reached $8.9 million, followed by Q2 2025 revenue of $9.41 million. The Trailing Twelve Month (TTM) revenue as of September 30, 2025, stood at $37.32 million. This segment is designed for efficiency, where the relationship is primarily governed by supply chain logistics and product availability rather than deep, ongoing consultation.

Dedicated support for key pharmaceutical wholesalers and pharmacies

While the generic distribution is transactional, the operational scale necessitates dedicated support structures to ensure product flow to key intermediaries. The company appointed Michel Roy as Chief Commercial Officer in Q1 2025, signaling an internal focus on optimizing commercial execution and likely managing relationships with major pharmaceutical wholesalers and pharmacy chains in Canada. The entry into specific, high-value generics, such as domperidone, which has a potential Canadian market opportunity exceeding $200 million, requires robust logistical and account management support for the distribution network. This support is about maintaining the transactional pipeline integrity.

• Secured Health Canada authorization for domperidone commercialization.
• Portfolio includes 70 generic prescription drugs on the market.
• Planned launch of 13 more drugs in late 2025.

High-touch engagement with academic and research partners

For the proprietary pipeline, customer relationships shift to a high-touch, collaborative model involving academic and research institutions. This engagement is critical for de-risking the development process. Sunshine Biopharma, Inc. is actively engaged in proprietary drug development, which involves external scientific expertise. For instance, a groundbreaking series of protease inhibitors for COVID-19 was developed in collaboration with the University of Arizona. Furthermore, the company has completed studies confirming the efficacy of its K1.1 mRNA Lipid Nanoparticle product for liver cancer, a process that inherently involves close interaction with research sites and investigators. These partners are essential for validating the science behind the high-potential, higher-margin therapeutics that represent the company's future growth vector.

Investor relations for NASDAQ-listed microcap company

As a NASDAQ-listed microcap company, investor relations form a distinct and crucial relationship category. The relationship management here focuses on transparency regarding financial performance and strategic milestones to maintain market confidence, especially given the company's ongoing unprofitability. The Q3 2025 Earnings Per Share (EPS) was reported at -$0.19, missing analyst expectations of -$0.12. The company's market capitalization as of November 13, 2025, was $8.19 million, with 4.91 million shares outstanding. A notable strategic move impacting investor perception was the investment of $5 million into a digital treasury asset, signaling an effort to bolster the balance sheet outside of traditional financing, which can soften dilution pressure. The risk profile is highlighted by a reported Sharpe ratio of -0.64, indicating poor risk-adjusted returns over the period. The stock price on October 16, 2025, was trending up by 19.68% amid optimism, though the stock price as of November 13, 2025, was $1.67.

Here's the quick math on the scale of the business as of late 2025:

Metric	Value (Late 2025)
TTM Revenue (as of Sep 30, 2025)	$37.32 million
Generic Drugs Marketed in Canada	70
Planned Generic Launches in Remainder of 2025	13
Market Capitalization (as of Nov 13, 2025)	$8.19 million
Shares Outstanding (Approximate)	4.91 million
Q3 2025 EPS	-$0.19
Investment in Digital Treasury Asset	$5 million

Finance: draft 13-week cash view by Friday.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Channels

You're looking at how Sunshine Biopharma, Inc. (SBFM) gets its products-mostly generics-into the hands of Canadian patients and prescribers as of late 2025. The channels are heavily weighted toward established pharmaceutical distribution networks in Canada, anchored by its subsidiary.

Nora Pharma, the Canadian distribution subsidiary

Nora Pharma Inc. is the core engine for Sunshine Biopharma's commercial channel strategy in Canada. This subsidiary specializes in the nationwide distribution of generic medications. The importance of this channel is clear in the financials; the acquisition of Nora Pharma in October 2022 added $10.7 million in revenue to the company's top line. This focus on generics is paying off, as the company marketed 72 generic prescription drugs in Canada as of late 2025, with 13 additional drugs planned for launch in the remainder of 2025. Revenue growth in fiscal year 2024, which jumped to $34,874,283, was directly attributed to expanded sales efforts and new product introductions by Nora Pharma. The expansion of Nora Pharma's operations also drove an increase in General and Administrative expenses to $16,481,915 in 2024. For the trailing twelve months ending September 30, 2025, Sunshine Biopharma's total revenue reached $37.32 million.

The recent Health Canada authorization for domperidone, commercialized via Nora Pharma, opens up a specific, high-value segment. The Canadian market for domperidone is described as an opportunity exceeding $200 million, representing 17% of the North American share, which itself accounts for 39% of the projected $1.36 billion in global domperidone sales for 2025. This regulatory win validates the channel strategy for regulated markets.

Here are some key metrics reflecting the scale of the Canadian distribution channel as of 2025 data:

Metric	Value (as of late 2025 data)	Context
Generics on Market in Canada	72	Current portfolio size through Nora Pharma.
Additional Drugs Planned for 2025 Launch	13	Pipeline of generics expected to enter the channel this year.
FY 2024 Revenue Attributed to Expansion	$34,874,283	Total revenue for the year ending December 31, 2024.
Q3 2025 Quarterly Revenue	$9.42 million	Revenue for the quarter ending September 30, 2025.
Projected Canadian Domperidone Market Size	>$200 million	Opportunity unlocked by Health Canada approval.

Pharmaceutical wholesalers and pharmacy chains in Canada

The actual movement of product to the end-user relies on established relationships with pharmaceutical wholesalers and pharmacy chains across Canada. Nora Pharma's specialization is in this nationwide distribution. The successful market entry of products like Prucalopride, which targets chronic constipation, demonstrates the channel's functionality for gastrointestinal drugs. Furthermore, the launch of gabapentin, a generic for nerve pain, shows the subsidiary's capability to execute on commercial distribution for various therapeutic areas. The company launched 6 new generics in Q1 2025 alone, all feeding into this established network.

The channel strategy involves:

• Securing distribution agreements with major Canadian wholesalers.
• Ensuring regulatory compliance for each product launch.
• Leveraging the existing infrastructure built by Nora Pharma.
• Targeting specific segments like chronic constipation and nerve pain.

Scientific publications and conferences for R&D pipeline visibility

While the commercial channel focuses on generics, visibility for the proprietary drug development pipeline is crucial for long-term valuation. This visibility is driven through scientific publications and conference presentations. The proprietary pipeline includes K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and a PLpro protease inhibitor for SARS Coronavirus infections. Progress in this channel was marked by studies confirming the efficacy of the K1.1 mRNA Lipid Nanoparticle product for liver cancer in Q1 2025. Specifically, additional orthotopic human tumor model studies in mice further confirmed K1.1 mRNA-LNP as a novel therapeutic for hepatocellular carcinoma during Q1 2025. This scientific validation is the primary output used to communicate progress in this non-commercial channel.

Direct-to-consumer sales for non-prescription products

Sunshine Biopharma, Inc. also has a focus on over-the-counter supplements in Canada alongside its prescription generics business. This represents a separate, though less detailed in public filings, channel for direct-to-consumer (DTC) engagement. While specific revenue figures for the OTC supplement line are not broken out from the overall Nora Pharma performance, the inclusion of this category suggests a dual-pronged approach to the Canadian market, capturing both prescription and wellness segments.

Finance: review Q3 2025 G&A spend relative to Q3 2025 revenue of $9.42 million to assess scaling efficiency by end of next week.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Customer Segments

You're looking at the specific groups Sunshine Biopharma, Inc. (SBFM) targets with its current offerings and pipeline as of late 2025. It's a mix of established commercial customers and future-facing clinical stakeholders, plus the capital providers funding the journey.

Canadian pharmaceutical wholesalers and retail pharmacies

This segment is the core revenue driver from the established generics business, primarily through its Nora Pharma arm, which focuses on reliable, repeatable therapeutic products in Canada. The company is actively expanding this base.

• Sunshine Biopharma, Inc. markets 70 generic prescription drugs on the market in Canada.
• The company planned to launch 13 additional drugs in the remainder of 2025.
• In the first quarter of 2025, 6 new generic prescription drugs were successfully launched.
• One of the planned launches for 2025 is NIOPEG®, a biosimilar of NEULASTA®.

Oncologists and healthcare providers treating cancer patients

This group is targeted by both the commercial portfolio and the proprietary drug development pipeline, which is heavily focused on oncology.

• The proprietary pipeline includes K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer (hepatocellular carcinoma).
• Additional lead programs involve anthracycline-based compounds like Bisantrene, which showed activity against breast and prostate cancer cell lines.
• Adva-27a, a novel analog, is being evaluated for glioblastoma multiforme and other drug-resistant malignancies.
• The biosimilar NIOPEG® is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.

Patients requiring generic and biosimilar medications

These are the end-users of the commercialized products, benefiting from access to necessary medications in the Canadian market.

The scale of the commercial offering directly addresses this segment's needs. Here's a quick look at the financial context supporting this customer base:

Metric	Value (Q1 2025 or Forecast 2025)
Q1 2025 Revenue	$8.9 million
Forecasted Annual Revenue (Average Analyst Estimate)	$188,653,209
Reported Annual Revenue (LTM as of Sep 2025)	$37.32 million
Gross Margin (Latest Reported)	33.3%

Institutional and retail investors in the biotech sector

This segment provides the necessary capital for operations and pipeline advancement. The company actively engages with this group through capital raises and market presence on NASDAQ.

• Sunshine Biopharma, Inc. closed a registered direct offering of approximately $2.46 million with institutional investors on April 3, 2025.
• The company made a strategic $5 million investment in Bitcoin as part of its strategic asset reserve to enhance treasury resilience.
• The stock trades on NASDAQ under the ticker SBFM.
• One Wall Street analyst has issued a 1-year price target of $7.00.
• The forecasted net loss for 2025 is approximately -$5,992,637.

The company's Q1 2025 revenue growth was 18% year-over-year, showing top-line momentum that appeals to this investor segment, defintely.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Cost Structure

The Cost Structure for Sunshine Biopharma, Inc. is heavily influenced by the dual nature of its business: maintaining a commercial generics operation while funding early-stage biopharmaceutical research.

High General and Administrative (G&A) expenses represent a significant fixed cost component. For the first quarter of 2025, G&A expenses were reported at $4.03 million. This figure reflected an 8.7% rise year-over-year, which management noted outpaced the increase in gross profit for that period, signaling ongoing operational pressure.

Cost of Goods Sold (COGS), or Cost of Revenue, is tied directly to the sales volume of the generic drug manufacturing and acquisition segment, primarily through Nora Pharma. For the quarter ending June 2025, the Cost of Revenue was reported at $6.0Mn. Based on Q1 2025 results, where Revenue was $8.90 million and Gross Profit was $2.73 million, the implied COGS for that quarter was approximately $6.17 million ($8.90 million minus $2.73 million).

The company continues to incur costs related to Significant Research and Development (R&D) expenditure for pipeline drugs. While specific R&D dollar amounts for Q1 2025 are not explicitly detailed in the G&A context, progress was noted on the K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma.

Costs associated with Regulatory compliance and clinical trial costs are inherent to the biopharma segment, particularly for advancing proprietary assets like the K1.1 program, though specific financial figures for these activities are not itemized in the readily available quarterly summaries.

Here is a look at some key cost-related metrics from the first half of 2025:

Cost Metric	Period	Amount
General and Administrative (G&A) Expenses	Q1 2025	$4.03 million
Cost of Revenue (COGS)	June 2025	$6.0Mn
Implied COGS	Q1 2025	Approximately $6.17 million
Net Loss	Q1 2025	$(1.18) million
Net Loss	Q2 2025	$1.77 million

The operational structure shows that G&A expenses of $4.03 million in Q1 2025 significantly exceeded the reported Gross Profit of $2.73 million for the same period, underscoring the challenge of covering overhead with current gross margins.

The company has expanded its commercial footprint, launching 6 new generic prescription drugs in Q1 2025, which contributes to the COGS base and associated operational costs.

• G&A expenses increased by 8.7% in Q1 2025 year-over-year.
• The generics portfolio included 70 products on the market, with 13 more slated for 2025.
• Q1 2025 revenue was $8.9 million.

Finance: draft 13-week cash view by Friday.

Sunshine Biopharma, Inc. (SBFM) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers driving Sunshine Biopharma, Inc.'s top line as of late 2025. The revenue streams are a mix of established generics and newer, higher-potential biosimilar entries, plus a novel treasury strategy.

The core revenue generation comes from the established generic prescription drug portfolio. For the first quarter of 2025, Sunshine Biopharma, Inc. reported total revenue of $8.9 million. This represented an 18% year-over-year growth compared to Q1 2024's $7.54 million.

Looking at the broader picture through the third quarter of 2025, the Trailing Twelve Month (TTM) revenue, ending September 30, 2025, stood at $37.32 million. This TTM figure reflects a 13.24% year-over-year growth. For the nine months ended September 30, 2025, the cumulative revenue was $27.728 million, which was up 9.7% compared to the same period in the prior year. The most recent quarterly figure, Q3 2025 revenue, was $9,417,179.

A significant new component to the revenue stream is the launch of new products, specifically the biosimilar NIOPEG®, through its Canadian subsidiary, Nora Pharma Inc.. This product is comparable to NEULASTA® (Pegfilgrastim). The global market for NEULASTA® and its biosimilars was estimated at $4.5 billion in 2024, with projections to reach $9.2 billion by 2033, showing a compound annual growth rate (CAGR) of 8.5%. The Canadian market for biologics was substantial, reaching $10 billion in 2020. At the time of the NIOPEG® launch, Sunshine Biopharma, Inc. already had 72 generic prescription drugs on the Canadian market, with plans to launch more than 12 additional drugs through the remainder of 2025.

Here's a quick look at the key revenue milestones as of late 2025:

• Sales from generics generated $8.9 million in Q1 2025.
• TTM revenue as of Q3 2025 was $37.32 million.
• Cumulative revenue for the first nine months of 2025 was $27.73 million.
• NIOPEG® targets a segment of the global market valued at $4.5 billion in 2024.

Sunshine Biopharma, Inc. also introduced a non-traditional revenue-related financial strategy. On October 14, 2025, the Board approved a strategic investment of $5 million in Bitcoin (BTC) as a treasury reserve asset. Management views this as a hedge and a high-conviction asset, with plans to increase holdings as funds become available.

You can see the recent revenue progression below:

Period	Revenue Amount	Change Metric
Q1 2025	$8.90 million	Up 18% Year-over-Year
Q3 2025 (Quarterly)	$9.42 million	Up 11.64% Year-over-Year
Nine Months Ended Sep 30, 2025 (Cumulative)	$27.73 million	Up 9.69% Year-over-Year
TTM Ended Sep 30, 2025	$37.32 million	Up 13.24% Year-over-Year

The company's strategy clearly involves scaling its existing generics business while using the cash flow to enter higher-margin areas like biosimilars with NIOPEG®, which is a key driver for future revenue diversification. Finance: draft 13-week cash view by Friday.